This partnership
is personal

Genomic solutions to change how cancer will be identified and treated

Future of NGS in Oncology

As genomics-focused pharmacology begins to play a greater role in cancer treatment, next-generation sequencing (NGS) has emerged as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. With targeted therapies becoming the new standard of care in oncology, NGS-driven companion diagnostics are widely seen as driving the selection of treatments to optimize patient outcomes in the future.

Compared to traditional methods, NGS offers advantages in accuracy, sensitivity, and speed that has the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, it eliminates the need to order multiple tests to identify the causative mutation.

This multigene approach decreases the time to answer, providing a more economical solution and reducing the risk of exhausting precious clinical samples. In addition, NGS can provide high sensitivity, enabling the detection of mutations present at as little as 5% of the DNA isolated from a tumor sample.

NGS has the potential to change the future of oncology and advance the promise of personalized medicine. We invite you to learn more by examining the resources collected here.

Oncology
Introduction to NGS in Oncology

Learn more about how NGS technology works and the advantages it offers over traditional methods in these in-depth introductions tailored to oncologists and molecular pathologists.

Introduction to NGS in Oncology

Jaclyn Hechtman, MD, Associate Attending Pathologist at Memorial Sloan Kettering Cancer Center, discusses the relevance of RET alterations in non-small cell lung cancer and the pros and cons of different technical approaches to identify RET fusions and single-nucleotide variants.

View Webinar
Lung Cancer

This next-generation sequencing approach consolidates hundreds of cancer-related biomarkers, including different variant types, into a single assay. Explore the benefits and find out how it compares to other common cancer NGS methods.

Learn More About CGP
ctDNA Analysis Samples
Transforming Diagnoses and Care for Acute Myeloid Leukemia
Transforming Diagnoses and Care for Acute Myeloid Leukemia

Illumina supports program to bring NGS technology to Latin America

Read Article
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories

Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.

Read Interview
Fighting For My Life, I Also Fought For Yours
Fighting For My Life, I Also Fought For Yours

By: Sandra Balladares, Ph.D., Global Marketing Manager at Illumina

Read Article
Tumor Mutational Burden (TMB)

NGS can help clinical cancer researchers estimate TMB, identify neoantigens, and study innovative therapies to boost the immune response.

Learn More
ctDNA Sequencing

NGS offers the sensitivity and specificity that clinical researchers need to detect low levels of circulating tumor DNA (ctDNA) in the bloodstream.

Learn More
Cancer Epigenetics

Explore the benefits of NGS and microarrays for analyzing altered methylation patterns and other epigenetic changes in cancer.

Learn More
Interested in receiving newsletters, case studies, and information on cancer genomics? Enter your email address.
Image
Genomic Applications in Oncology

The Medical Affairs team at Illumina discusses the applications of genomics in oncology for risk prediction and precision medicine.

Learn More
Francis deSouza Speaks at Aspen Ideas: Health
Francis deSouza Speaks at Aspen Ideas: Health

Francis deSouza, President and CEO of Illumina, shares his views on actions needed to bring genomics to the patients who need it.

Read Article
Image
Medical Genetics Education

Find educational resources about medical genetics and learn how genomic information can be used in clinical practice.

Learn More